

Anjali S Advani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7188599/publications.pdf>

Version: 2024-02-01

106
papers

3,863
citations

218677

26
h-index

128289

60
g-index

107
all docs

107
docs citations

107
times ranked

3919
citing authors

#	ARTICLE	IF	CITATIONS
1	Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 740-753.	27.0	1,047
2	Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 2085-2093.	1.6	306
3	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019, 133, 1548-1559.	1.4	292
4	Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. <i>Cancer</i> , 2019, 125, 2474-2487.	4.1	210
5	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. <i>Blood</i> , 2021, 137, 751-762.	1.4	183
6	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. <i>Lancet Haematology</i> , 2017, 4, e387-e398.	4.6	158
7	Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1831-1839.	1.6	112
8	Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. <i>Blood Advances</i> , 2017, 1, 1167-1180.	5.2	103
9	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1079-1109.	4.9	96
10	TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. <i>Blood Advances</i> , 2020, 4, 5011-5024.	5.2	85
11	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2113-2123.	2.0	77
12	SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 165, 504-509.	2.5	73
13	NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1091-1102.	4.9	67
14	Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010, 151, 430-434.	2.5	57
15	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1720-1729.	2.0	53
16	SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 1574-1582.	1.6	44
17	Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. <i>Blood Cancer Journal</i> , 2018, 8, 4.	6.2	43
18	Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2017, 98, 425-434.	2.2	41

#	ARTICLE	IF	CITATIONS
19	<scp>SWOG</scp>0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2014, 167, 233-237.	2.5	39
20	Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1135-1146.	1.4	39
21	Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. <i>Leukemia Research</i> , 2008, 32, 913-918.	0.8	37
22	Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 591-591.	1.4	35
23	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. <i>Blood Advances</i> , 2019, 3, 4228-4237.	5.2	34
24	Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. <i>Blood Cancer Journal</i> , 2020, 10, 81.	6.2	34
25	Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1117-1121.	2.0	32
26	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. <i>Leukemia Research</i> , 2020, 88, 106283.	0.8	32
27	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. <i>Blood</i> , 2021, 138, 1885-1895.	1.4	32
28	Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. <i>Blood Advances</i> , 2020, 4, 2308-2316.	5.2	29
29	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 504-512.	5.2	28
30	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021, 35, 2076-2085.	7.2	28
31	Management of older adults with acute lymphoblastic leukemia: challenges & current approaches. <i>International Journal of Hematologic Oncology</i> , 2018, 7, IJH02.	1.6	26
32	Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients. <i>BMC Cancer</i> , 2010, 10, 387.	2.6	23
33	Genomics of therapy-related myeloid neoplasms. <i>Haematologica</i> , 2020, 105, e98-e101.	3.5	23
34	FLT3 and Acute Myelogenous Leukemia: Biology, Clinical Significance and Therapeutic Applications. <i>Current Pharmaceutical Design</i> , 2005, 11, 3449-3457.	1.9	22
35	Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2005, 106, 230-230.	1.4	19
36	Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 2536-2542.	1.3	18

#	ARTICLE	IF	CITATIONS
37	OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 606-612.	1.3	17
38	A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia. <i>Leukemia Research</i> , 2010, 34, 1622-1626.	0.8	16
39	<i>BCOR</i> and <i>BCORL1</i> mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes. <i>Leukemia and Lymphoma</i> , 2019, 60, 1587-1590.	1.3	16
40	Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 1039-1048.	4.1	16
41	A Phase II Trial of Gemcitabine and Mitoxantrone for Patients With Acute Myeloid Leukemia in First Relapse. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 473-476.	0.4	14
42	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 556-560.e2.	0.4	12
43	Histone H4 acetylation by immunohistochemistry and prognosis in relapsed acute lymphocytic leukaemia (ALL). <i>British Journal of Haematology</i> , 2011, 153, 504-507.	2.5	11
44	Quality-of-Life Trajectories in Adolescent and Young Adult versus Older Adult Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1505-1510.	2.0	11
45	Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. <i>Bone Marrow Transplantation</i> , 2021, 56, 1998-2004.	2.4	11
46	Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia. <i>Future Oncology</i> , 2015, 11, 1729-1739.	2.4	10
47	Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. <i>Leukemia and Lymphoma</i> , 2020, 61, 2012-2015.	1.3	10
48	Distinctive and common features of moderate aplastic anaemia. <i>British Journal of Haematology</i> , 2020, 189, 967-975.	2.5	10
49	Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 4085-4092.	5.2	10
50	Toxicities of Intravenous (IV) Pegasparginase (ONCASPAR®) in Adults with Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2007, 110, 2811-2811.	1.4	9
51	Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2013, 122, 3906-3906.	1.4	9
52	Prognostic Factors for Post-Transplant Outcomes in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2011, 118, 2015-2015.	1.4	9
53	TP53 Mutations and Outcome in Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 4336-4336.	1.4	8
54	Time to post-remission therapy is an independent prognostic factor in adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 1560-1566.	1.3	6

#	ARTICLE	IF	CITATIONS
55	Treatment of Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>Journal of Adolescent and Young Adult Oncology</i> , 2011, 1, 19-24.	1.3	5
56	Ribosomal S6 Kinase and AKT Phosphorylation as Pharmacodynamic Biomarkers in Patients With Myelodysplastic Syndrome Treated With RAD001. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 172-177.e1.	0.4	5
57	Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. <i>Leukemia and Lymphoma</i> , 2021, 62, 735-738.	1.3	5
58	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. <i>Blood</i> , 2019, 134, 261-261.	1.4	5
59	AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker. <i>Scientific Reports</i> , 2022, 12, 5809.	3.3	5
60	Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 489-495.	0.4	4
61	Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. <i>Leukemia and Lymphoma</i> , 2018, 59, 363-371.	1.3	4
62	A Phase II Trial of Imatinib Mesylate as Maintenance Therapy for Patients With Newly Diagnosed C-kit ⁺ positive Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 113-118.	0.4	4
63	A Phase II Study of Lenalidomide for Previously Untreated Deletion (del) 5q Acute Myeloid Leukemia (AML) Patients Age 60 or Older Who Are Not Candidates for Remission Induction Chemotherapy (Southwest Oncology Group Study S0605). <i>Blood</i> , 2010, 116, 332-332.	1.4	4
64	A Phase I Study of Sequential Idarubicin + Cytarabine, Followed by Lenalidomide, in Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2011, 118, 2600-2600.	1.4	4
65	Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 776-7.	0.3	4
66	Perspectives and Future Directions for Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S6-S9.	0.4	3
67	Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. <i>British Journal of Haematology</i> , 2020, 191, e77-e81.	2.5	3
68	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 917.e1-917.e9.	1.2	3
69	Non-Cytotoxic Differentiation Therapy Based On Mechanism of Disease Produces Complete Remission in Myelodysplastic Syndromes (MDS) with High Risk Cytogenetics. <i>Blood</i> , 2012, 120, 1696-1696.	1.4	3
70	Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2020, 61, 1943-1953.	1.3	2
71	Molecular and Immunophenotypic Characteristics of Adult Acute Leukemias of Ambiguous Lineage. <i>Blood</i> , 2016, 128, 1659-1659.	1.4	2
72	Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): Analysis from INO-VATE by bone marrow blast percentage (BMB%).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7028-7028.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Exploration of Potential Relationships between CD22 and Selected Safety Outcomes in the Inotuzumab Ozogamicin Phase 3 INO-VATE Study. <i>Blood</i> , 2018, 132, 4031-4031.	1.4	1
74	Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay. <i>Blood</i> , 2018, 132, 4806-4806.	1.4	1
75	RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2696-2696.	1.4	1
76	Race and Intensity of Post-Remission Therapy in Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2009, 114, 1012-1012.	1.4	1
77	Splicing Factor 3b Subunit 1 (SF3B1) mediates Mitochondrial Iron Overload In Myelodysplastic Syndromes With Ring Sideroblasts By Alternative Splicing Of Mitoferrin-1 (SLC25A37). <i>Blood</i> , 2013, 122, 1555-1555.	1.4	1
78	Extensive safety profile of inotuzumab ozogamicin (InO) in relapsed/refractory acute lymphoblastic leukemia (ALL) patients enrolled in the phase 3 INO-VATE trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7029-7029.	1.6	1
79	Time to Nadir Peripheral White Blood Cell Count (WBC) and Absolute WBC Nadir Value Following Induction Chemotherapy in Older Adults with Acute Myeloid Leukemia (AML) Predicts Survival.. <i>Blood</i> , 2004, 104, 1074-1074.	1.4	1
80	APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11047-11047.	1.6	1
81	Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML. <i>Blood</i> , 2015, 126, 1350-1350.	1.4	1
82	A Double-Blind, Placebo-Controlled, Phase 3 Registration Trial to Evaluate the Efficacy of Uproleselan (GMI-1271) with Standard Salvage Chemotherapy in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 2650-2650.	1.4	1
83	A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia (AML) Undergoing Remission Induction Therapy. <i>Blood</i> , 2019, 134, 2595-2595.	1.4	1
84	Epsilon Aminocaproic Acid (EACA) Reduces Transfusion Requirements in Patients with Thrombocytopenic Hemorrhage.. <i>Blood</i> , 2004, 104, 3938-3938.	1.4	0
85	The Relationship between Weekend Admissions and Outcome in Older Adults with Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2004, 104, 3140-3140.	1.4	0
86	Survival and Predictors of Outcome in Acute Leukemia Patients Admitted to the Intensive Care Unit.. <i>Blood</i> , 2005, 106, 2778-2778.	1.4	0
87	Cytogenetic Classification Systems and Overall Survival Following Bone Marrow Transplant (BMT) for Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2005, 106, 4500-4500.	1.4	0
88	CD117 Expression Is a Poor Prognostic Factor (PF) for Progression Free Survival (PFS) and Freedom from Progression (FFP) in Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2005, 106, 3292-3292.	1.4	0
89	Prognostic Factors and Outcomes of Patients with Acute Myeloid Leukemia (AML) Receiving Non Intensive Chemotherapy (NIC) or Best Supportive Care (BSC).. <i>Blood</i> , 2006, 108, 4492-4492.	1.4	0
90	Prior Therapy with Rituximab (R) in Patients with Follicular Lymphoma (FL) Does Not Affect Relapse-Free (RFS) or Overall Survival (OS) after High Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT).. <i>Blood</i> , 2006, 108, 3069-3069.	1.4	0

#	ARTICLE	IF	CITATIONS
91	OCT-2 Expression and OCT-2/BOB.1 Co-Expression Predict Prognosis in Patients with Newly Diagnosed Acute Myelogenous Leukemia.. Blood, 2008, 112, 1486-1486.	1.4	0
92	High Rate of Survival in Transformed Lymphoma after Autologous Stem Cell Transplant (ASCT): Pathologic Analysis and Comparison with De Novo DLBCL.. Blood, 2008, 112, 1137-1137.	1.4	0
93	A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.. Blood, 2008, 112, 955-955.	1.4	0
94	Impact of Weekend Admissions on Quality of Care and Outcomes in Patients with Acute Myeloid Leukemia (AML).. Blood, 2008, 112, 1942-1942.	1.4	0
95	The Value of Post-Remission Therapy in Older Adults with Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 1043-1043.	1.4	0
96	Strong Histone (H4) Acetylation Is Independently Associated with Better Overall Survival in Newly Diagnosed Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 4681-4681.	1.4	0
97	New TET2, ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders. Blood, 2010, 116, 3076-3076.	1.4	0
98	Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) Is Associated with An Increased Risk of Death In Acute Myeloid Leukemia.. Blood, 2010, 116, 1675-1675.	1.4	0
99	Prognostic Significance of Histone (H4) Acetylation In Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with Intermediate Risk Cytogenetics. Blood, 2010, 116, 2736-2736.	1.4	0
100	Radiation Treatment for Localized Prostate Cancer and the Risk of Developing Myelodysplastic Syndromes (MDS). Blood, 2011, 118, 120-120.	1.4	0
101	The Impact of Molecular Lesions in Post-Transplant Acute Myeloid Leukemia (AML) in Correlation with Cytogenetic Abnormalities,. Blood, 2011, 118, 4137-4137.	1.4	0
102	Association of MHC Class I Chain-Related Gene a (MICA) Polymorphisms with Allogeneic Hematopoietic Cell Transplantation Outcomes in Acute Myeloid Leukemia. Blood, 2018, 132, 2075-2075.	1.4	0
103	Differences in Genomic Patterns between African Americans and Whites with Acute Myeloid Leukemia. Blood, 2018, 132, 1527-1527.	1.4	0
104	Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States. Blood, 2018, 132, 371-371.	1.4	0
105	CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q). Blood, 2019, 134, 1281-1281.	1.4	0
106	G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL. Blood Advances, 2022, , .	5.2	0